ArticleInternational journal of clinical and experimental pathology2020
Expression of circRNA circ_0026344 in gastric cancer and its clinical significance.
Article in International journal of clinical and experimental pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hsa_circ_0026344 suppresses gastric cancer progression via modulating the miR-1290/FBP2 axis.Histology and histopathology · 2023Article
- hsa_circ_0001955 Promotes Colorectal Cancer Progression by Regulating miR-583/FGF21 Axis.Journal of oncology · 2022Article
- Comprehensive Analysis of Differentially Expressed circRNAs Reveals a Colorectal Cancer-Related ceRNA Network.Computational and mathematical methods in medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence indicates that circular RNAs (circRNAs) are a novel class of biomarkers and therapeutic targets in malignancies. Circ_0026344 has been reported to be downregulated in colorectal cancer, and associated with prognosis. However, little is currently known regarding its expression and clinical significance in gastric cancer. In this study, we evaluated the expression level of circ_0026344 in two previous circRNAs chips (GSE78092 and GSE89143) for gastric cancer. 93 pairs of gastric cancer and adjacent non-tumour tissues were collected, and qRT-PCR was applied to determine circ_0026344 expression. The level of circ_0026344 in gastric cancer cells (MKN45 and AGS) and a normal gastric epithelial cell line (GES-1) was also analyzed. Chi-square test was used to identify the association between circ_0026344 level and clinicopathologic factors. Kaplan-Meier method with log-rank test was applied to compare survival curves. Cox regression analyses were used to assess the prognostic value of circ_0026344. In GSE24549 and GSE24550 datasets, downregulation of circ_0026344 was observed. In 93 cases of gastric cancer, circ_0026344 in cancer tissues was significantly decreased compared to adjacent non-cancerous tissues, and its level was markedly associated with tumour size, lymph node metastasis, TNM stage, and invasive depth. Furthermore, patients with lower expression of circ_0026344 showed significantly worse overall survival than those with higher expression. Additional, circ_0026344 expression was an independent predictor for overall survival. Summarily, our study highlights that downregulation of circ_0026344 is associated with tumour malignant behavior and it is a potential biomarker for gastric cancer prognosis.
Indexed as
Identifiers
32509073PMC7270661What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.